<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kezar Life Sciences Inc — News on 6ix</title>
<link>https://6ix.com/company/kezar-life-sciences-inc</link>
<description>Latest news and press releases for Kezar Life Sciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kezar-life-sciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358f1578dffbe2df1017ab.webp</url>
<title>Kezar Life Sciences Inc</title>
<link>https://6ix.com/company/kezar-life-sciences-inc</link>
</image>
<item>
<title>Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/enodia-therapeutics-strengthens-sec61-portfolio-through-acquisition-of-preclinical-assets-from-kezar-life-sciences-7</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/enodia-therapeutics-strengthens-sec61-portfolio-through-acquisition-of-preclinical-assets-from-kezar-life-sciences-7</guid>
<pubDate>Thu, 12 Mar 2026 13:00:00 GMT</pubDate>
<description>PARIS & SOUTH SAN FRANCISCO, Calif., March 12, 2026--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Enodia has acquired Kezar’s assets from its Sec61-based discovery and development program. The acqui</description>
</item>
<item>
<title>Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-regulatory-110100659</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-regulatory-110100659</guid>
<pubDate>Fri, 09 Jan 2026 11:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., January 09, 2026--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune</description>
</item>
<item>
<title>Kezar Life Sciences Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-third-210100919</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-third-210100919</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 12, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-presentation-120100615</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-presentation-120100615</guid>
<pubDate>Fri, 07 Nov 2025 12:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., November 07, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the completed Phase 2a PORTOLA clinical trial in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025 held by the American Association for the Study of Liver Disease (AASLD) and taking place November 7-11, in Washington, DC.</description>
</item>
<item>
<title>Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-regulatory-200500448</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-regulatory-200500448</guid>
<pubDate>Thu, 16 Oct 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., October 16, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory updates and the initiation of a process to explore a full range of strategic alternatives focused on maximizing shareholder value. The Company has retained TD Cowen to support it with the strategic review process.</description>
</item>
<item>
<title>Kezar Life Sciences to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-participate-two-200100326</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-participate-two-200100326</guid>
<pubDate>Thu, 28 Aug 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., August 28, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September:</description>
</item>
<item>
<title>Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-second-200100595</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-second-200100595</guid>
<pubDate>Wed, 13 Aug 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., August 13, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-fda-204100414</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-fda-204100414</guid>
<pubDate>Tue, 15 Jul 2025 20:41:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 15, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in pat</description>
</item>
<item>
<title>Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-participate-jefferies-200100533</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-participate-jefferies-200100533</guid>
<pubDate>Wed, 28 May 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 28, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY.</description>
</item>
<item>
<title>Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-first-200100789</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-first-200100789</guid>
<pubDate>Tue, 13 May 2025 20:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 13, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-positive-113000993</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-positive-113000993</guid>
<pubDate>Tue, 25 Mar 2025 11:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 25, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results.</description>
</item>
<item>
<title>Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-present-topline-120000618</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-present-topline-120000618</guid>
<pubDate>Mon, 24 Mar 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, CALIF., March 24, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET.</description>
</item>
<item>
<title>Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-present-virtual-210100758</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-present-virtual-210100758</guid>
<pubDate>Tue, 18 Feb 2025 21:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 18, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present at a virtual Key Opinion Leader (KOL) event hosted by William Blair on zetomipzomib clinical development in autoimmune hepatitis (AIH) and will also provide a safety update from the PALIZADE Phase 2b clinical trial in patients with active l</description>
</item>
<item>
<title>Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-third-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-third-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>Topline data from PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH) expected in first half 2025 Cash, cash</description>
</item>
<item>
<title>Kezar Life Sciences Announces 1-for-10 Reverse Stock Split</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-1-for-10-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-1-for-10-reverse-stock-split</guid>
<pubDate>Mon, 28 Oct 2024 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small</description>
</item>
<item>
<title>Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-board-unanimously-rejects-unsolicited-concentra-proposal-and-adopts-limited-duration-stockholder-rights-plan</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-board-unanimously-rejects-unsolicited-concentra-proposal-and-adopts-limited-duration-stockholder-rights-plan</guid>
<pubDate>Thu, 17 Oct 2024 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small</description>
</item>
<item>
<title>Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-positive-idmc-safety-review-of-portola-trial-of-zetomipzomib-in-patients-with-autoimmune-hepatitis-and-provides-palizade-update</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-positive-idmc-safety-review-of-portola-trial-of-zetomipzomib-in-patients-with-autoimmune-hepatitis-and-provides-palizade-update</guid>
<pubDate>Thu, 17 Oct 2024 04:00:00 GMT</pubDate>
<description>PORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring</description>
</item>
<item>
<title>Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-clinical-hold-of-zetomipzomib-ind-for-treatment-of-lupus-nephritis</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-clinical-hold-of-zetomipzomib-ind-for-treatment-of-lupus-nephritis</guid>
<pubDate>Fri, 04 Oct 2024 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small</description>
</item>
<item>
<title>Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-cessation-of-enrollment-and-dosing-in-the-phase-2b-palizade-trial-of-zetomipzomib-in-active-lupus-nephritis-patients</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-announces-cessation-of-enrollment-and-dosing-in-the-phase-2b-palizade-trial-of-zetomipzomib-in-active-lupus-nephritis-patients</guid>
<pubDate>Mon, 30 Sep 2024 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small</description>
</item>
<item>
<title>Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-second-quarter-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/kezar-life-sciences-inc/news/kezar-life-sciences-reports-second-quarter-2024-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 13 Aug 2024 04:00:00 GMT</pubDate>
<description>Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first</description>
</item>
</channel>
</rss>